| Pheophorbide a is a specific probe for ABCG2 function and inhibition RW Robey, K Steadman, O Polgar, K Morisaki, M Blayney, P Mistry, ... Cancer research 64 (4), 1242-1246, 2004 | 413 | 2004 |
| Single nucleotide polymorphisms modify the transporter activity of ABCG2 K Morisaki, RW Robey, C Özvegy-Laczka, Y Honjo, O Polgar, ... Cancer chemotherapy and pharmacology 56, 161-172, 2005 | 272 | 2005 |
| ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy RW Robey, K Steadman, O Polgar, SE Bates Cancer biology & therapy 4 (2), 195-202, 2005 | 248 | 2005 |
| ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis M Rotinen, S You, J Yang, SG Coetzee, M Reis-Sobreiro, WC Huang, ... Nature medicine 24 (12), 1887-1898, 2018 | 138 | 2018 |
| Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T‐cell lymphoma SE Bates, Z Zhan, K Steadman, T Obrzut, V Luchenko, R Frye, RW Robey, ... British journal of haematology 148 (2), 256-267, 2010 | 85 | 2010 |
| Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure RW Robey, S Shukla, K Steadman, T Obrzut, EM Finley, SV Ambudkar, ... Molecular cancer therapeutics 6 (6), 1877-1885, 2007 | 72 | 2007 |
| Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas-deficient MRL/lpr−/− murine model of autoimmune lymphoproliferative … KC Dowdell, L Pesnicak, V Hoffmann, K Steadman, AT Remaley, ... Experimental hematology 37 (4), 487-494, 2009 | 64 | 2009 |
| Emerin deregulation links nuclear shape instability to metastatic potential M Reis-Sobreiro, JF Chen, T Novitskaya, S You, S Morley, K Steadman, ... Cancer Research 78 (21), 6086-6097, 2018 | 55 | 2018 |
| Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanes S Morley, S You, S Pollan, J Choi, B Zhou, MH Hager, K Steadman, ... Scientific reports 5 (1), 12136, 2015 | 53 | 2015 |
| Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells J Panicker, Z Li, C McMahon, C Sizer, K Steadman, R Piekarz, SE Bates, ... Cell cycle 9 (9), 1830-1838, 2010 | 48 | 2010 |
| Pharmacogenomic characterization of gemcitabine response–a framework for data integration to enable personalized medicine M Harris, K Bhuvaneshwar, T Natarajan, L Sheahan, D Wang, ... Pharmacogenetics and genomics 24 (2), 81-93, 2014 | 40 | 2014 |
| Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen JF Deeken, RW Robey, S Shukla, K Steadman, AR Chakraborty, ... Molecular pharmacology 76 (5), 946-956, 2009 | 36 | 2009 |
| The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems ME Goldsmith, A Aguila, K Steadman, A Martinez, SM Steinberg, MC Alley, ... Molecular Cancer Therapeutics 6 (2), 496-505, 2007 | 33 | 2007 |
| Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure MA Rudek, CY Chang, K Steadman, MD Johnson, N Desai, JF Deeken Cancer chemotherapy and pharmacology 73, 729-736, 2014 | 30 | 2014 |
| A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies JF Deeken, H Wang, D Subramaniam, AR He, J Hwang, JL Marshall, ... Cancer 121 (10), 1645-1653, 2015 | 29 | 2015 |
| PolyHEMA spheroids are an inadequate model for the drug resistance of the intractable solid tumors K Steadman, WD Stein, T Litman, SX Yang, M Abu-Asab, SK Dutcher, ... Cell Cycle 7 (6), 818-829, 2008 | 18 | 2008 |
| Valproic Acid (VPA), a Histone Deacetylase (HDAC) Inhibitor, Diminishes Lymphoproliferation in the Fas Deficient MRL/lpr−/− Murine Model of Autoimmune Lymphoproliferative … KC Dowdell, L Pesnicak, V Hoffman, K Steadman, M Ruddel, VK Rao, ... Blood 108 (11), 2497, 2006 | 10 | 2006 |
| Small Bowel Location, Stricturing Behavior, Vitamin D Receptor Polymorphism, and Metabolic Disease Susceptibility Genes Are Associated with NAFLD in Crohn’s Disease: 1704 S Chhina, K Steadman, G Goel, K Nguyen, S Targan, X Li, T Haritunians, ... Official journal of the American College of Gastroenterology| ACG 109, S504, 2014 | 3 | 2014 |
| Final results of a phase I study of lapatinib (LAP) and cetuximab (CET) in patients with CET-sensitive solid tumors. JF Deeken, H Wang, J Marshall, DS Subramaniam, JJ Hwang, AR He, ... Journal of Clinical Oncology 31 (15_suppl), 2616-2616, 2013 | 3 | 2013 |
| Efficacy of combining targeted therapies cetuximab and dasatinib for resistant salivary gland carcinomas in vitro. A Brohl, K Steadman, B Kallakury, JF Deeken Journal of Clinical Oncology 28 (15_suppl), 5557-5557, 2010 | 3 | 2010 |
